RSK2: a promising therapeutic target for the treatment of triple-negative breast cancer

  • Expert Opin Ther Targets. 2020 Jan;24(1):1-5. doi: 10.1080/14728222.2020.1709824.
My-My Huynh  1 ,  Aarthi Jayanthan  1 ,  Mary Rose Pambid  1 ,  Gerrit Los  2 ,  Sandra E Dunn  1  2
Affiliations
  • 1. Phoenix Molecular Designs, Vancouver, British Columbia, Canada.
  • 2. Phoenix Molecular Designs, San Diego, CA, USA.
PMID: 31875730 DOI: 10.1080/14728222.2020.1709824
Keywords
Kinase inhibitors; RSK2; targeted therapy; triple-negative breast cancer (TNBC).
Products